Perlinganite, ampoules 0.1%, 10ml, 10pcs

Composition

1 ampoule with 10 ml of infusion solution contains 10 mg nitroglycerin in an isotonic 5% glucose solution.

Pharmacological action

Perlinganite has a vasodilating, antianginal effect.

Indications

Angina pectoris (unstable and vasospastic), acute myocardial infarction, acute left ventricular failure, hypertensive crisis on the background of heart failure, controlled hypotension.

Contraindications

Acute circulatory failure (shock, vascular collapse); severe hypotension (systolic blood pressure below 95 mm Hg); cardiogenic shock (with simultaneous use of drugs with a positive inotropic effect or balloon counterpulsation).

Side effects

Headache, drowsiness, weakness, decreased blood pressure, tachycardia, nausea, vomiting.

Interaction

When used concomitantly with other vasodilators (vasodilators), antihypertensive drugs, beta-blockers, calcium channel blockers, phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction (for example, sildenafil), neuroleptics, tricyclic antidepressants, and ethanol, the hypotensive effect may increase.

With simultaneous use of Perlinganit with dihydroergotamine, an increase in the concentration of dihydroergotamine in the blood may occur, which leads to an increase in its hypotensive effect.

With the simultaneous use of heparin and Perlinganite, the effect of heparin may be weakened. Under the control of blood clotting parameters, the appropriate dose of heparin is selected. After stopping the infusion of Perlinganit, a significant decrease in blood clotting may occur, which may require a reduction in the dose of heparin.

When using a solution of perlinganite and a tissue plasminogen activator simultaneously, a decrease in blood concentration and a decrease in the effectiveness of the latter are described.

How to take, course of use and dosage

Perlinganite is administered intravenously, through a perfuser. Doses are selected individually, usually 0.75-10.0 mg/h.

Overdose

Symptoms: a sharp decrease in blood pressure, reflex rapid pulse, a feeling of general weakness, dizziness and lethargy, as well as headache, redness of the skin of the face or upper body, nausea, vomiting and diarrhea. When using the drug in high doses (more than 20 mg/kg of body weight), methemoglobinemia, cyanosis, shortness of breath and tachypnea may develop; an increase in intracranial pressure with cerebral symptoms may occur.

Treatment: it is necessary to monitor the function of vital organs.

In cases of severe hypotension and / or shock, the volume of circulating blood should be increased; in exceptional cases, an infusion of norepinephrine (norepinephrine) and/or dopamine can be performed. The use of epinephrine (epinephrine) and related substances is contraindicated.

For methemoglobinemia, depending on the severity, the following antidotes are recommended: ascorbic acid (1 g orally or iv in the form of sodium salt); methylene blue (up to 50 mg of a 1% solution of methylene blue iv); toluidine blue (an initial dose of 2-4 mg/kg of body weight iv; if necessary, repeated at hourly intervals of 2 mg/kg of body weight). Oxygen therapy, hemodialysis, and blood transfusion are indicated.

Special instructions

Infusion systems made of polyethylene, polypropylene, polytetrafluoroethylene or glass should be used (but not polyvinyl chloride and polyurethane, as they adsorb the Active ingredient and therefore may require an increase in the dose).

Storage conditions

At room temperature no higher than 25 °C

Shelf life

5 years

Active ingredient

Nitroglycerin

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution